Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.04 USD | -1.30% | +2.01% | +7.04% |
Feb. 14 | Transcript : Aytu BioPharma, Inc., Q2 2024 Earnings Call, Feb 14, 2024 | |
Feb. 14 | Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M | MT |
Evolution of the average Target Price on Aytu BioPharma, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Aytu BioPharma, Inc.
Maxim | |
HC Wainwright | |
Cantor Fitzgerald |
EPS Revisions
- Stock
- Equities
- Stock Aytu BioPharma, Inc. - Nasdaq
- Consensus Aytu BioPharma, Inc.